Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new class of acid blocker called tegoprazan relieved reflux symptoms significantly faster than the standard PPI pantoprazole in non-Asian adults with erosive esophagitis — but didn't outperform it on healing damaged tissue at 4 weeks. In the first week of treatment, 84% of tegoprazan patients hit the 50% symptom relief mark vs. just 31% on pantoprazole. The findings mark the first randomized trial of this drug in a Latin American population.
Faster relief, but healing is a draw — for now
A new randomized trial out of Mexico put tegoprazan, a potassium-competitive acid blocker (P-CAB), head-to-head against pantoprazole, a widely used proton pump inhibitor (PPI), in 70 non-Asian adults with moderate-to-severe erosive esophagitis. The headline result: tegoprazan didn't significantly outperform pantoprazole on the primary goal of endoscopic healing at 4 weeks — but it did deliver noticeably faster symptom relief in the first week of treatment.
This is notable because most evidence for P-CABs like tegoprazan has come from Asian populations, where the drug has shown strong results. This trial is the first randomized controlled data in Latin American patients, expanding the evidence base for a drug that could offer a meaningful alternative to standard PPIs.
By the Numbers
Why it matters: For patients suffering from painful reflux symptoms, faster relief is a meaningful clinical advantage. While tegoprazan didn't clinch a clear healing advantage overall, its speed of symptom control — and potential edge in severe cases — could make it a compelling option, especially as clinicians look beyond PPIs for GERD management.
